Extavia er blevet undersøgt gennem to år hos 338 patienter, der havde relapsing- remitterende dissemineret sklerose, og som selv kunne gå.
Extavia was studied over a two year period in 338 patients with relapsing remitting MS and able to walk unaided, where its effectiveness was compared with placebo (a dummy treatment).